Target trial does not suggest major adverse outcomes with early GLP-1 use in pregnancy

MedicalXpress | Jun 08, 2026

A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate a substantially increased risk for nonlive birth, abnormal fetal growth, or major congenital malformation with continuation of GLP-1RAs into the first trimester.